Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's true I didn't look at it like that. But, back to the whole "fully funded by bioheart" thing again. Are they wordsmith-ing here? That could mean will fund the entire trial, when they the funds. Or, it could mean that it's already paid for. At this point though Comella said that it's dependent on obtaining the necessary funding. Another conundrum...
Furthermore, in 2x blind study not even the physicians should know who is getting real treatment vs. placebo. So why would it be an issue to announce how many patients are currently enrolled.
Unbelievable. She completely dodged our main question. You can give enrollment numbers without saying how many patients were the placebo. It also doesn't clearly state if trials are currently enrolling and operational. You could use that statement about any business, that continuing operations is dependent upon obtaining the necessary funding. Continuing life is dependent upon obtaining the necessary oxygen. That doesn't mean that you're currently breathing.
What's his email?
Didn't you already ask Mike that question about Mirror enrollment numbers a few months back and wasn't his response that it would be addressed in this 10-K? How could he be not know that people are curious about the main project at Bioheart. Will you please stay on him about this issue. We need to hear an update on where Mirror stands, whether the info is good or bad.
Didn't you already ask Mike that question about Mirror enrollment numbers a few months back and wasn't his response that it would be addressed in this 10-K? How could he be not know that people are curious about the main project at Bioheart. Will you please stay on him about this issue. We need to hear an update on where Mirror stands, whether the info is good or bad.
What about this:
During the year ended December 31, 2013, 1,000,000 shares of common stock were issued to the debt holder valued at $19,500, in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations. As of December 31, 2013 the remaining principle of this note was $500,000.
If I'm reading this right, they issued a million shares and got a significant amount of debt paid off. I've also noticed that they have continued to pay off debt since last year...
Two news stories today (technically) and such low volume? Doesn't make sene. Let's see what the rest of the day holds.
Thanks for the response. Seems a little wishy-washy to on the one hand say that the enrollment update will be out around January, then to contradict and say there will be info in the 10-Q. Either way I guess we will have our answer. Maybe it will be the last piece of news before the 10-Q.
Has emailed Mike Tomas asking about when there would be an update on patient enrollment. I recall someone mentioning that he gave a timeframe which has passed. Can you ask him again?
So how do you think the street will take the 10-Q IF it is announced that the outstanding issued share count has increased?
Seems like if there are poor enrollment numbers for mirror and more dilution this thing go opposite of what everyone is hoping.
But I think strong mirror enrollment numbers will trump all other news.
DONT SELL!
How many shares are authorized? Sorry if this question had been answered already. I thought that shares increases had to be approved by the board of directors as well as the common shareholders. Any additional info surrounding this topic would be great.
Thanks
Just not enough volume we need more money pumping through
guys let's throw some money at this thing and keep it moving up.
I realize that, but that doesn't mean that they are without regulation. The public will still view these cells as embryonic stem cells regardless of whether or not the embryo they are derived from is preserved. Does anyone know what the actual law states at this point, because there most definitely is one.
All,
I'm as hopeful as the rest of you are about the idea of being granted breakthrough status by the FDA. My only concern is what is the current political climate with hesc cells? Are they even eligible for widespread clinical sale? Would the FDA perhaps not be inclined to grant BTS simply based on the controversial nature of hesc?
is that supposed to be related to SLNN making their own EV? Because based on the last press release, that doesn't seem like the case. I think you're misunderstanding the quote that you posted.
That's not what it reads like to me. Looks like they won't be producing their own EV.
That's not what it reads like to me. Looks like they won't be producing their own EV.
You can't just simply uplist! The stock price has to meet certain criteria and hold those criteria for a certain amount of time. Basically, it will have to stay at or above a certain price for some period of time. Chances are that after the reverse split the stock will be at or near the required levels, then will plummet much before it has maintained those levels for the specified time.
Yes the R/S does out weigh what you have mentioned.
How can you guys not understand that there is a reverse split and an additional 1 billion shares on the horizon for this company. These are both seen as hugely negative for the company. You can't simply be "in it for the science, not the CEO", both go hand in hand. I have a degree in molecular biology and have followed this company for years. At times I have owned the stock, currently I do not. The technology is cutting edge and I have no doubt that overall, biotech will create this country's next economic surplus.